GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.